FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB API	PROVAL
OMB Number:	3235-02

OMB Number: 3235-0287
Estimated average burden hours per response: 0.5

# Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Marstiller Jean W  (Last) (First) (Middle)  2525 WEST END AVE.  SUITE 950  (Street)  NASHVILLE TN 37203					3. D 03/	2. Issuer Name and Ticker or Trading Symbol CUMBERLAND PHARMACEUTICALS INC [ CPIX ]  3. Date of Earliest Transaction (Month/Day/Year) 03/24/2011  4. If Amendment, Date of Original Filed (Month/Day/Year)									S. Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director 10% Owner     X Officer (give title Other (specify below) below)     Sr. VP & Corp. Secretary      6. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person					
(City)	(St		Zip)																	
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					action Day/Yea	ay/Year)  2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transa Code ( 8)	ction	4. Securit Disposed 5)	ties Ad	Acquired (A) or f (D) (Instr. 3, 4 and (D) (D) Price		nd	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Owners Form: Dir (D) or Ind (I) (Instr. 4	ect irect	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock  03/24/2011  A 3,000(1)  A \$0.00 430,816  D  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Executio curity or Exercise (Month/Day/Year) if any		3A. Deeme Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)			ative rities ired sesed . 3, 4	Expiratio (Month/D	Date Exercisable and Expiration Date Month/Day/Year)  Date Expiration Date Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)  Amour or Numbe of Title Shares		ount nber	nt er		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owne Form Direct or Ind (I) (Ins	(D) irect	11. Nature of Indirect Beneficial Ownership (Instr. 4)

#### **Explanation of Responses:**

1. Restricted stock award will vest 100% on March 24, 2015.

## Remarks:

Jean W. Marstiller by: /s/ David L. Lowrance as attorney-in-fact

03/25/2011

attorney-in-fact
\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.